BPC-157 legal status (October 2026): BPC-157 is not an approved drug and cannot currently be compounded under federal rules. FDA put it in Category 2 (significant safety risks) on September 29, 2023, then removed it in April 2026 after the nominators withdrew.[1][2] On July 23, 2026, FDA’s advisory committee voted 8–6 (one abstention) to recommend adding it to the 503A bulks list, but FDA has not acted on that advice.[6] WADA has banned it in sport since 2022.[8]
For what BPC-157 is and the research behind it, see our BPC-157 profile and the healing peptides hub.
BPC-157 legal status at a glance
| Question | Answer (October 2026) |
|---|---|
| Approved drug in the U.S.? | No |
| Controlled substance? | No |
| On FDA’s 503A bulks list? | No[3] |
| In Category 1 (compounding tolerated)? | No[3] |
| In Category 2? | No; listed as “nominated but withdrawn” since April 2026[2] |
| Advisory committee view | 8–6 in favor of the 503A list, July 23, 2026[6] |
| FDA staff view | Against adding it[5] |
| Sport (WADA) | Prohibited at all times, class S0[8] |
How BPC-157 ended up in Category 2
FDA builds the 503A bulks list from nominations. While it reviews them, it sorts nominated ingredients into Category 1 (under evaluation), Category 2 (significant safety risks) or Category 3 (inadequate support). Only Category 1 gets interim tolerance for compounding.[3] See 503A vs 503B compounding for how the system works.
In its September 29, 2023 update, FDA added BPC-157 to Category 2, alongside several other peptides including AOD-9604, cathelicidin LL-37 and injectable GHK-Cu.[1]
FDA’s safety concerns
FDA’s significant-safety-risks page still summarizes its concerns about BPC-157:[2]
- Immunogenicity: compounded BPC-157 may pose a risk of immune reactions for certain routes.
- Impurities and characterization: peptide-related impurities and the active ingredient are hard to characterize.
- Missing safety data: FDA found no, or only limited, safety information for the proposed routes, so it cannot say whether the drug would cause harm in people.
Human data remain thin. The only published intravenous safety report we found involved two adults given up to 20 mg; no adverse events were reported, but a two-person study cannot establish safety.[9]
The April 2026 withdrawal
In April 2026, FDA removed 12 peptides, including BPC-157, from Category 2 because the nominators withdrew their nominations; BPC-157’s two nominators were Wells Pharmacy Network and LDT Health Solutions.[5][7] FDA’s May 14, 2026 category list shows only six substances left in Category 2, and its safety page lists 17 peptides and other substances as “nominated but withdrawn.”[3][2]
Sources give different dates for this step. Law-firm summaries describe an April 15 announcement, and FDA’s withdrawn-nominations page was updated April 22, 2026. Either way, removal from Category 2 does not by itself put a substance in Category 1, and BPC-157 does not appear in FDA’s Category 1 list.[3][7]
The July 2026 advisory committee vote
FDA chose to evaluate BPC-157 on its own initiative even after the withdrawal, and took it to the Pharmacy Compounding Advisory Committee (PCAC) on July 23, 2026.[4][5] The nomination was for ulcerative colitis, as oral capsules and subcutaneous injection.[5]
FDA staff recommended against listing it. The briefing said BPC-157 is not well characterized, lacks safety and immunogenicity information, lacks evidence of effectiveness for ulcerative colitis, and that approved treatments for that serious disease exist.[5] The committee voted 8–6 with one abstention to recommend it anyway.[6]
| Peptide (July 23–24, 2026) | Vote (yes–no) | Outcome |
|---|---|---|
| BPC-157 | 8–6, 1 abstention | Recommended[6] |
| KPV | 8–6 | Recommended[7] |
| TB-500 | 8–6 | Recommended[7] |
| MOTS-c | 7–5 | Recommended[7] |
| Emideltide (DSIP) | 6–7 | Not recommended[7] |
| Epitalon | 7–4 | Recommended[7] |
| Semax | 8–5 | Recommended[7] |
Vote counts other than BPC-157’s come from a law-firm summary; FDA had not posted final minutes on its meeting page when we checked.[4]
What would have to happen next
For BPC-157 to become lawful to compound under Section 503A, FDA would have to take one of two steps:
- Rulemaking: publish a proposed rule in the Federal Register adding BPC-157 to the 503A bulks list, take public comments, then issue a final rule amending 21 CFR 216.23.
- Interim tolerance: place BPC-157 in Category 1 while it decides, which would signal that FDA does not intend to act against 503A compounding with it.
One law-firm analysis expects rulemaking in 2027 at the earliest and says it could take several years; it also notes that FDA usually follows PCAC advice, though it is not required to.[7] Even if BPC-157 is listed, it would apply only to 503A pharmacies filling prescriptions for individual patients. Outsourcing facilities under Section 503B use a separate list based on clinical need.
FDA has said it plans to consult the PCAC again before the end of February 2027 on GHK-Cu, another peptide from the April 2026 group.[3]
Can pharmacies compound BPC-157 now?
Not under federal law today. Section 503A lets a pharmacy compound with a bulk ingredient only if it has a USP or NF monograph, is a component of an approved drug, or appears on the 503A bulks list.[10] BPC-157 meets none of these, and it is not in Category 1, the group FDA tolerates while it decides.[3] Products sold as “research use only” are not legal for human use either; see research-use-only peptides.
WADA and sport
WADA added BPC-157 to class S0, non-approved substances, on the list that took effect January 1, 2022, and it is named in S0 on the 2026 list. S0 covers drugs with no government approval for human use and is prohibited at all times.[8] Athletes in tested sport can face a violation whatever the label says. See peptides on the WADA prohibited list.
State actions
States regulate pharmacies and clinicians through boards of pharmacy and medicine. Because federal rules don’t allow compounding BPC-157, state boards can treat it as a violation of state pharmacy law, and some states have stricter rules than federal law. We did not find a state statute specifically addressing BPC-157 as of October 2026; check your state boards for current notices.
What it means for you
- Stacks and blends: the same limits apply to products combining BPC-157 with other peptides; see the BPC-157 and TB-500 Wolverine stack, the GLOW blend and the KLOW blend.
- Watch for FDA rulemaking: any change would appear in the Federal Register with a comment period.
- Talk to a clinician about approved options for your condition.
This is general information, not legal advice. BPC-157’s status may change quickly after the 2026 advisory vote.
